[Sar9,Met(O2)11]-Substance P TFA structure
|
Common Name | [Sar9,Met(O2)11]-Substance P TFA | ||
---|---|---|---|---|
CAS Number | 110880-55-2 | Molecular Weight | 1393.655 | |
Density | 1.4±0.1 g/cm3 | Boiling Point | N/A | |
Molecular Formula | C64H100N18O15S | Melting Point | N/A | |
MSDS | USA | Flash Point | N/A |
Use of [Sar9,Met(O2)11]-Substance P TFA[Sar9,Met(O2)11]-Substance P is a tachykinin NK1 receptor selective agonist. |
Name | [Sar9, Met(O2)11]-Substance P |
---|---|
Synonym | More Synonyms |
Description | [Sar9,Met(O2)11]-Substance P is a tachykinin NK1 receptor selective agonist. |
---|---|
Related Catalog | |
Target |
NK1 receptor[1] |
In Vitro | [Sar9,Met(O2)11]-Substance P and septide (10-100 pmol per rat, i.c.v.) are equipotent in increasing mean arterial blood pressure (MAP) and heart rate (HR), yet they have dissimilar time-course. Both agonists increase dose-dependently face washing and sniffing while [Sar9,Met(O2)11]-Substance P is the sole to produce grooming[1]. |
Kinase Assay | Rats initially receive an i.c.v. injection of artificial cerebrospinal fluid (aCSF; 1 μl) followed 60 min later by a single dose of either [Sar9,Met(O2)11]-Substance P (10 pmol (n=9), 25 pmol (n=9), 65 pmol (n=8) or 100 pmol (n=8)) or septide (10 pmol (n=12), 25 pmol (n=9), 65 pmol (n=6) or 100 pmol (n=6)) to construct a complete dose-response curve. Each rat is selected randomly and injected with only one of the two agonists for the remainder of the protocol. Increasing doses of [Sar9,Met(O2)11]-Substance P or septide are given at 24 h intervals on day 1 (10 pmol), day 2 (25 pmol), day 3 (65 pmol) and day 4 (100 pmol). Control rats (n=18) receive only the vehicle (aCSF) each day of experiment. Peptides are administered in a volume of 1 μL of vehicle followed by 5 μL flush volume of aCSF which corresponds to the void volume of the catheter. Each dose is calculated per rat in 1 μL solution[1]. |
References |
Density | 1.4±0.1 g/cm3 |
---|---|
Molecular Formula | C64H100N18O15S |
Molecular Weight | 1393.655 |
Exact Mass | 1392.733643 |
PSA | 550.36000 |
LogP | -1.99 |
Index of Refraction | 1.657 |
Storage condition | −20°C |
Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
---|---|
RIDADR | NONH for all modes of transport |
WGK Germany | 3 |
Effect of melatonin on the vasopressin secretion as influenced by tachykinin NK-1 receptor agonist and antagonist: in vivo and in vitro studies.
J. Physiol. Pharmacol. 58(4) , 829-43, (2007) The aim of the present study was to investigate the influence of melatonin on vasopressin (AVP) release from the rat hypothalamo-neurohypophysial (H-NH) system, both in vivo and in vitro, possibly mod... |
|
Differential role of neurokinin receptors in human lymphocyte and monocyte chemotaxis.
Regul. Pept. 96 , 17-21, (2000) The precise nature of neurokin receptor involvement in human immune cell chemotaxis is unclear. This study therefore sought to directly compare the chemotactic effects of neurokinins on human T lympho... |
|
Neurokinin receptor modulation of respiratory activity in the rabbit.
Eur. J. Neurosci. 27(12) , 3233-43, (2008) The respiratory role of neurokinin (NK) receptors was investigated in alpha-chloralose-urethane-anaesthetized, vagotomized, paralysed and artificially ventilated rabbits by using bilateral microinject... |
L-Leucinamide, N-(diaminomethylene)-L-ornithyl-L-prolyl-L-lysyl-L-prolyl-L-glutaminyl-L-glutaminyl-L-phenylalanyl-L-phenylalanyl-N-methylglycyl-N-[(1S)-1-(aminocarbonyl)-3-(methylsulfonyl)propyl]- |
[Sar9,Met(O2)11]-Substance P |
N-(Diaminomethylene)-L-ornithyl-L-prolyl-L-lysyl-L-prolyl-L-glutaminyl-L-glutaminyl-L-phenylalanyl-L-phenylalanyl-N-methylglycyl-N-[(2S)-1-amino-4-(methylsulfonyl)-1-oxo-2-butanyl]-L-leucinamide |
MFCD00076787 |